Ara 290 vs HGH
Extensively Studied vs FDA Approved
synergistic Mechanism-based · 55% Ara 290 and HGH work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Ara 290 HGH
Weight 1,257 Da 22,124 Da
Half-life ~20 minutes (SubQ), ~2 minutes (IV) 3-4 hours (SC), 20-30 minutes (IV)
Chain 11 amino acids 191 amino acids
Type Engineered peptide Single-chain polypeptide with two disulfide bridges
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Research Evidence
Ara 290 HGH
Status Extensively Studied FDA Approved
References 5 studies 4 studies
Latest 2024 2024
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.